This article is more than 5 years old. Information may no longer be current.

June's top 5 retina stories

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

June’s most read articles focusing on retina news included breaking news regarding a new IOL for patients with AMD, as well as regulatory and business updates.

Here are the top 5 most popular retinal articles of the month on Healio.com/OSN:

Magnifying lens improves vision, quality of life in patients with advanced AMD and cataract

A foldable design makes the lens implantable through a small incision, similar to a normal IOL. Read more.

Bevacizumab used more frequently than ranibizumab for Medicare beneficiaries with DME

In a sample of Medicare beneficiaries from the Medicare Part B claims from 2010 to 2013, a greater proportion of patients with DME were treated with Avastin (bevacizumab, Genentech) compared with Lucentis (ranibizumab, Genentech). Read more.

First Argentinian patient receives EyeMax Mono lens for AMD

The first EyeMax Mono lens implant procedure for age-related macular degeneration was performed in Argentina. Read more.

Ophthotech partners with University of Florida, Penn for gene therapy development

Ophthotech has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania to develop and commercialize a novel adeno-associated virus gene therapy product to treat rhodopsin-mediated autosomal dominant retinitis pigmentosa. Read more.

Lin Bioscience’s Stargardt disease treatment gets European orphan drug designation

The European Medicines Agency granted orphan drug designation to Lin BioScience’s Stargardt disease treatment LBS-008, an oral therapy that prevents the buildup of toxins in the eye that cause Stargardt disease and atrophic age-related macular degeneration. The treatment received orphan drug designation from the FDA in 2017. Read more.